Bayer sells a minority stake in its contraceptives business to Apollo Global Management in a deal valued at about €3 billion (around $3.4 billion), according to multiple reports. The transaction is described as a financing arrangement that provides Bayer with cash proceeds meant to strengthen its capital position and improve its balance sheet. Financial terms are reported in both euros and dollars depending on the outlet.
Several sources say Bayer intends to use the funds to bolster its capital structure following years of legal expenses related to claims involving its Roundup weedkiller. The sale reduces Bayer’s ownership in the contraceptives unit while allowing it to retain a continuing stake.
Apollo is identified as the buyer, and the contraceptives business is consistently cited as the asset being partially sold. The reports do not provide additional details on governance or the size of Apollo’s ownership beyond describing it as a minority stake. The transaction is therefore presented primarily as a capital-raising step tied to Bayer’s ongoing litigation costs and broader financial priorities.
